Table 1.
Status of HCMV vaccines and antibody-based therapeutics with clinical data.
| Vaccine/mAb | Key Features | Status |
|---|---|---|
| Towne (Wistar) | Attenuated live virus, lacking pentameric complex | Effective in transplant but not in congenital |
| gB/MF59 (Sanofi) | Recombinant subunit vaccine with adjuvant | Effective in ~50% of subjects |
| Cytotect™ (Europe) Cytogam™ (US) | Hyper Immune Globulin (HIG) has shown efficacy in both transplant and congenital indications | Marketed products |
| ASP0113 (Vical, Astellas) | 2 plasmid DNA vaccine (pp65, gB) induced only weak responses to gB | Development suspended after Phase 3 |
| MSL-109 (Sandoz) | Binds gH, but efficacy is reduced by uptake of Ab-Ag complex into cells | Development suspended after Phase 3 |
| RG7667 (Genentech) | 2 mAbs, one targeting gH (similar to MSL-109), and one targeting the pentameric complex | Development suspended after Phase 2 |
| CSJ148 (Novartis) | 2 mAbs, one targeting gB (AD-4), and one targeting the pentameric complex | Development suspended after Phase 2 |
| TCN-202 (Theraclone) | Human mAb against gB (AD-2, Site I) | Development suspended after Phase 2 |